Patents by Inventor Zachary Shriver

Zachary Shriver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF USING INTERLEUKIN-2 AGENTS
    Publication number: 20240376173
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: July 26, 2024
    Publication date: November 14, 2024
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • Methods of using interleukin-2 agents
    Patent number: 12098178
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Grant
    Filed: December 3, 2021
    Date of Patent: September 24, 2024
    Assignees: Visterra, Inc., The General Hospital Corporation
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Thiago de Jesus Borges, Leonardo Vidal Riella
  • ANTIBODY MOLECULES TO CD138 AND USES THEREOF
    Publication number: 20240301065
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Application
    Filed: February 20, 2024
    Publication date: September 12, 2024
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • Interleukin-2 agents and uses thereof
    Patent number: 12084484
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: September 10, 2024
    Assignee: Visterra, Inc.
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • Antibody molecules to dengue virus and uses thereof
    Patent number: 12054539
    Abstract: Antibody molecules that specifically bind to dengue virus are disclosed. In certain embodiments, the antibody molecule bind to dengue virus serotypes DV-1, DV-2, DV-3, and DV-4. The antibody molecules can be used to treat, prevent, and/or diagnose dengue virus.
    Type: Grant
    Filed: July 7, 2021
    Date of Patent: August 6, 2024
    Assignee: VISTERRA, INC.
    Inventors: Luke Robinson, Zachary Shriver, James R. Myette, Gregory Babcock, Karthik Viswanathan
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20240247040
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: March 25, 2024
    Publication date: July 25, 2024
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan
  • Ha binding agents
    Patent number: 12024552
    Abstract: This disclosure relates to novel peptide agents, e.g., antibodies and antigen-binding fragments thereof, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Grant
    Filed: August 14, 2020
    Date of Patent: July 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Karthik Viswanathan, Vidya Subramanian, Sasisekharan Raguram
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20240150488
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: September 29, 2023
    Publication date: May 9, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • BINDING POLYPEPTIDES AND METHODS OF MAKING THE SAME
    Publication number: 20240141334
    Abstract: Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Application
    Filed: October 5, 2023
    Publication date: May 2, 2024
    Inventors: Zachary Shriver, Gregory Babcock, Luke Robinson
  • Antibody molecules to CD138 and uses thereof
    Patent number: 11945868
    Abstract: Antibody molecules that specifically bind to CD138 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as multiple myeloma.
    Type: Grant
    Filed: October 2, 2018
    Date of Patent: April 2, 2024
    Assignee: VISTERRA, INC.
    Inventors: Bharat Chaganty, Boopathy Ramakrishnan, Hedy Adari-Hall, Karthik Viswanathan, James R. Myette, Zachary Shriver
  • ANTIBODY MOLECULES TO APRIL AND USES THEREOF
    Publication number: 20240092921
    Abstract: Antibody molecules that specifically bind to APRIL are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as IgA nephropathy.
    Type: Application
    Filed: April 24, 2023
    Publication date: March 21, 2024
    Inventors: David William Oldach, James R. Myette, Zachary Shriver, Karthik Viswanathan, Andrew M. Wollacott, Hedy Adari-Hall, Boopathy Ramakrishnan, Gregory Babcock, Jill Yarbrough, Asher Schachter, Mohit Mathur
  • Antibody Molecules to C5AR1 and Uses Thereof
    Publication number: 20240076398
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Application
    Filed: August 18, 2023
    Publication date: March 7, 2024
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • Humanized complement 5A receptor 1 antibodies and methods of use thereof
    Patent number: 11912781
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Grant
    Filed: January 13, 2022
    Date of Patent: February 27, 2024
    Assignee: Visterra, Inc.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver, Lauren Olinski
  • Antibody molecule-drug conjugates and uses thereof
    Patent number: 11890319
    Abstract: Antibody molecule-drug conjugates (ADCs) that specifically bind to lipopolysaccharides (LPS) are disclosed. The antibody molecule-drug conjugates can be used to treat, prevent, and/or diagnose bacterial infections and related disorders.
    Type: Grant
    Filed: January 18, 2018
    Date of Patent: February 6, 2024
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Obadiah Joseph Plante, Kai Li, Karthik Viswanathan, James C. Delaney, Boopathy Ramakrishnan, Andrew M. Wollacott
  • IMMUNOSILENCING Fc VARIANTS
    Publication number: 20230416372
    Abstract: The present disclosure provides, among other things Fc variants that have significantly reduced ADCC, ADCP and CDC function As described herein, the present disclosure is, in part based on identification of novel combinations of mutations that abolish binding to all Fc?RI, Fc?RIIa, Fc?RIIb, Fc?RIIIa, Fc?RIIb, and C1q.
    Type: Application
    Filed: August 29, 2023
    Publication date: December 28, 2023
    Applicant: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Lauren Olinski, Ramki Ramakrishnan, Aditi Deshpande, Gregory Babcock, Zachary Shriver
  • Binding polypeptides and methods of making the same
    Patent number: 11820979
    Abstract: Polypeptides, such as antibody molecules and TCR molecules, and methods of making the same, are disclosed. The polypeptides can be used to treat, prevent, and/or diagnose disorders.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: November 21, 2023
    Assignee: VISTERRA, INC.
    Inventors: Zachary Shriver, Gregory Babcock, Luke Robinson
  • Antibody molecules to C5aR1 and uses thereof
    Patent number: 11773179
    Abstract: Antibody molecules that specifically bind to C5aR1 are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as ANCA-vasculitis.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 3, 2023
    Assignee: VISTERRA, INC.
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING INFLUENZA
    Publication number: 20230257449
    Abstract: This disclosure relates to binding agents, e.g., antibody molecules, that bind hemagglutinin protein of influenza viruses, and methods of their use.
    Type: Application
    Filed: December 11, 2020
    Publication date: August 17, 2023
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew M. Wollacott, Gregory Babcock, Zachary Shriver
  • HUMANIZED COMPLEMENT 5A RECEPTOR 1 ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20220356263
    Abstract: The present disclosure provides, among other things, two different formats of humanized antibodies against human complement component 5a receptor I. The disclosure also provides a method of treating a subject having dysfunctions of C5a/C5aR1 axis pathway, including but not limited to ANCA-associated vasculitis, comprising administering to the subject in need thereof a an effective amount of antibody or a nucleic encoding an antibodies binding to C5aR1 described herein, and wherein administering results in a decrease in symptoms associated with C5a/C5aR1 associated dysfunction in the subject.
    Type: Application
    Filed: January 13, 2022
    Publication date: November 10, 2022
    Inventors: Karthik Viswanathan, Brian Booth, Boopathy Ramakrishnan, Andrew Wollacott, Gregory Babcock, Zachary Shriver
  • INTERLEUKIN-2 AGENTS AND USES THEREOF
    Publication number: 20220226442
    Abstract: IL-2 agents that comprise IL-2 variants are disclosed as well as methods, compositions, and uses thereof. The IL-2 agents described herein can be used to treat and/or prevent various disorders and conditions.
    Type: Application
    Filed: January 20, 2022
    Publication date: July 21, 2022
    Inventors: Scott Moore Carlson, Gregory Babcock, Zachary Shriver, Boopathy Ramakrishnan, Susan Sloan